| Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials A Lin, CJ Giuliano, A Palladino, KM John, C Abramowicz, ML Yuan, ... Science translational medicine 11 (509), 2019 | 548 | 2019 |
| Structure of the mitochondrial inner membrane AAA+ protease YME1 gives insight into substrate processing C Puchades, AJ Rampello, M Shin, CJ Giuliano, RL Wiseman, SE Glynn, ... Science 358 (6363), 2017 | 204 | 2017 |
| CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials A Lin, CJ Giuliano, NM Sayles, JM Sheltzer Elife 6, e24179, 2017 | 133 | 2017 |
| Generating single cell–derived knockout clones in mammalian cells with CRISPR/Cas9 CJ Giuliano, A Lin, V Girish, JM Sheltzer Current protocols in molecular biology 128 (1), 2019 | 127 | 2019 |
| MELK expression correlates with tumor mitotic activity but is not required for cancer growth CJ Giuliano, A Lin, JC Smith, AC Palladino, JM Sheltzer Elife 7, e32838, 2018 | 87 | 2018 |
| B-cell-specific checkpoint molecules that regulate anti-tumour immunity L Bod, YC Kye, J Shi, E Torlai Triglia, A Schnell, J Fessler, SM Ostrowski, ... Nature, 1-9, 2023 | 38 | 2023 |
| FABP1 controls hepatic transport and biotransformation of Δ 9-THC MW Elmes, LE Prentis, LL McGoldrick, CJ Giuliano, JM Sweeney, ... Scientific reports 9 (1), 1-13, 2019 | 22 | 2019 |
| A positive feedback loop controls Toxoplasma chronic differentiation MH Licon, CJ Giuliano, AW Chan, S Chakladar, JN Eberhard, ... Nature microbiology, 1-16, 2023 | 20 | 2023 |
| Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11 A Lin, CJ Giuliano, A Palladino | 17 | 2019 |
| Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11: eaaw8412 A Lin, CJ Giuliano, A Palladino, KM John, C Abramowicz, ML Yuan, ... | 17 | 2019 |
| Functional profiling of the Toxoplasma genome during acute mouse infection CJ Giuliano, KJ Wei, FM Harling, BS Waldman, MA Farringer, ... bioRxiv, 2023.03. 05.531216, 2023 | 8 | 2023 |
| Abstract B44: Lysyl oxidases suppress pancreatic cancer progression and inhibit FAK and ERK signaling M Shields, P Maguin, C Giuliano, S Dallas, JE Wilkinson, M Egeblad Cancer Research 78 (10 Supplement), B44-B44, 2018 | | 2018 |
| Identification and characterization of survival-associated genomic features across tumor types J Smith, A Lin, C Giuliano, JM Sheltzer Cancer Research 77 (13 Supplement), 390-390, 2017 | | 2017 |
| Abstract 2149A: CRISPR/Cas9 mutagenesis invalidates a genetic target of clinical trials in cancer A Lin, C Giuliano, N Sayles, J Smith, J Sheltzer Cancer Research 77 (13 Supplement), 2149A-2149A, 2017 | | 2017 |
| Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancer CJ Giuliano, A Lin, JC Smith, AC Palladino, JM Sheltzer BioRxiv, 203984, 2017 | | 2017 |
